Population Genetics Technologies

About Population Genetics Technologies

Population Genetics Technologies (PGT), a Cambridge, UK-based company founded in 2005, operated in the biotechnology sector, focusing on developing tools to make large-scale population genetic studies more efficient. The company was co-founded by Nobel Laureate Dr. Sydney Brenner, Dr. Sam Eletr, and Dr. Philip Goelet. Dr. Eletr has a notable background, having also founded Applied Biosystems, which developed successful DNA sequencing machines, and Lynx Therapeutics, a pioneer in next-generation sequencing technologies. PGT emerged from concepts for studying populations proposed by Dr. Brenner and was initially supported by seed funding from the Wellcome Trust's Technology Transfer Division.

The firm's core business involved the development and subsequent out-licensing of biochemical tools and methodologies, termed "chemware," for next-generation sequencing (NGS) applications. This strategy centered on licensing its intellectual property to companies in the infectious disease molecular diagnostics and life science tools sectors that had the resources to commercialize the technologies. PGT's technology was designed to tackle the significant costs and complexities associated with preparing samples for NGS, thereby enabling the simultaneous analysis of hundreds or thousands of genomes in a single assay. This addressed a key bottleneck in genomics research, where identifying rare genetic variants often required prohibitively expensive re-sequencing of many individual genomes. The company's IP portfolio, comprising over 30 patents, covered methods to improve the accuracy, reduce the complexity and cost, and analyze the phasing of NGS.

One of its notable proprietary technologies was VeriTag™, which enhanced the sensitivity of NGS to detect mutations in pathogens at very low frequencies, such as 0.1%. PGT also developed the Reflex™ technology for the efficient targeted sequencing of long DNA regions across a large number of samples, a platform-agnostic method successfully used on Roche 454, Ion Torrent, and Illumina systems. The company engaged in collaborations with biopharmaceutical firms like Quintiles to integrate genomic testing into mainstream drug development for areas including renal cancer, breast cancer, leukemia, and Alzheimer's disease. It also licensed patent rights to major industry players, including Agilent Technologies and New England Biolabs. Over its lifetime, PGT raised a total of $18.4 million in funding over several rounds from investors such as Auriga Partners, Noble Fund Managers, and Syngenta Group Ventures. The company is now listed as out of business, having undergone liquidation.